[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.92.239. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Download PDF
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram. FOBT indicates fecal occult blood testing.

Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram. FOBT indicates fecal occult blood testing.

Figure 2. Completion rates by study arm. Participants recommended colonoscopy completed screening at a significantly lower rate than participants recommended fecal occult blood testing (FOBT) or a choice between colonoscopy or FOBT. The level of statistical significance was reduced to .01 to adjust for multiple comparisons.

Figure 2. Completion rates by study arm. Participants recommended colonoscopy completed screening at a significantly lower rate than participants recommended fecal occult blood testing (FOBT) or a choice between colonoscopy or FOBT. The level of statistical significance was reduced to .01 to adjust for multiple comparisons.

Figure 3. Adherence by study arm and race/ethnicity. Among participants offered a choice of screening tests, white participants adhered more often to colonoscopy than nonwhite participants (odds ratio [OR], 3.2; 95% CI, 1.7-6.1), and less often to fecal occult blood testing (FOBT) (OR, 0.3; 95% CI, 0.1-0.6). Among participants offered FOBT, Asians (OR, 2.6; 95% CI, 1.2-5.3) and Latinos (OR, 2.1; 95% CI, 1.0-4.2) adhered more often than whites.

Figure 3. Adherence by study arm and race/ethnicity. Among participants offered a choice of screening tests, white participants adhered more often to colonoscopy than nonwhite participants (odds ratio [OR], 3.2; 95% CI, 1.7-6.1), and less often to fecal occult blood testing (FOBT) (OR, 0.3; 95% CI, 0.1-0.6). Among participants offered FOBT, Asians (OR, 2.6; 95% CI, 1.2-5.3) and Latinos (OR, 2.1; 95% CI, 1.0-4.2) adhered more often than whites.

Table 1. Baseline Sociodemographic Characteristics of the Participants by Study Arm
Table 1. Baseline Sociodemographic Characteristics of the Participants by Study Arm
Table 2. Adherence to Colorectal Cancer Screening Strategiesa
Table 2. Adherence to Colorectal Cancer Screening Strategiesa
1.
Wilson JMG, Jungner F. Principles and Practice of Screening for Disease. Geneva, Switzerland: World Health Organization; 1968
2.
Hardcastle JD, Chamberlain JO, Robinson MH,  et al.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.  Lancet. 1996;348(9040):1472-1477PubMedArticle
3.
Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test.  Lancet. 1996;348(9040):1467-1471PubMedArticle
4.
Mandel JS, Bond JH, Church TR,  et al.  Reducing mortality from colorectal cancer by screening for fecal occult blood: Minnesota Colon Cancer Control Study.  N Engl J Med. 1993;328(19):1365-1371PubMedArticle
5.
Mandel JS, Church TR, Bond JH,  et al.  The effect of fecal occult-blood screening on the incidence of colorectal cancer.  N Engl J Med. 2000;343(22):1603-1607PubMedArticle
6.
Selby JV, Friedman GD, Quesenberry CPJ Jr, Weiss NS. Effect of fecal occult blood testing on mortality from colorectal cancer: a case-control study.  Ann Intern Med. 1993;118(1):1-6PubMed
7.
Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality.  J Natl Cancer Inst. 1992;84(20):1572-1575PubMedArticle
8.
Selby JV, Friedman GD, Quesenberry CPJ Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer.  N Engl J Med. 1992;326(10):653-657PubMedArticle
9.
Atkin WS, Edwards R, Kralj-Hans I,  et al; UK Flexible Sigmoidoscopy Trial Investigators.  Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial.  Lancet. 2010;375(9726):1624-1633PubMedArticle
10.
Winawer SJ, Zauber AG, Ho MN,  et al; The National Polyp Study Workgroup.  Prevention of colorectal cancer by colonoscopic polypectomy.  N Engl J Med. 1993;329(27):1977-1981PubMedArticle
11.
Müller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer: a case-control study among veterans.  Arch Intern Med. 1995;155(16):1741-1748PubMedArticle
12.
Müller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy: a case-control study of 32,702 veterans.  Ann Intern Med. 1995;123(12):904-910PubMed
13.
Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the US Preventive Services Task Force.  Ann Intern Med. 2002;137(2):132-141PubMed
14.
US Preventive Services Task Force.  Screening for colorectal cancer: US Preventive Services Task Force recommendation statement.  Ann Intern Med. 2008;149(9):627-637PubMed
15.
Levin B, Lieberman DA, McFarland B,  et al; American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.  Gastroenterology. 2008;134(5):1570-1595PubMedArticle
16.
Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM.American College of Gastroenterology.  American College of Gastroenterology guidelines for colorectal cancer screening 2009 [published correction appears in Am J Gastroenterol. 2009 Jun;104(6):1613].  Am J Gastroenterol. 2009;104(3):739-750PubMedArticle
17.
Maxwell AE, Crespi CM, Antonio CM, Lu P. Explaining disparities in colorectal cancer screening among five Asian ethnic groups: a population-based study in California.  BMC Cancer. 2010;10:214PubMedArticle
18.
Doubeni CA, Laiyemo AO, Klabunde CN, Young AC, Field TS, Fletcher RH. Racial and ethnic trends of colorectal cancer screening among Medicare enrollees.  Am J Prev Med. 2010;38(2):184-191PubMedArticle
19.
Vijan S, Hwang EW, Hofer TP, Hayward RA. Which colon cancer screening test? a comparison of costs, effectiveness, and compliance.  Am J Med. 2001;111(8):593-601PubMedArticle
20.
Heisler M, Cole I, Weir D, Kerr EA, Hayward RA. Does physician communication influence older patients' diabetes self-management and glycemic control? results from the Health and Retirement Study (HRS).  J Gerontol A Biol Sci Med Sci. 2007;62(12):1435-1442PubMedArticle
21.
Stewart MA. Effective physician-patient communication and health outcomes: a review.  CMAJ. 1995;152(9):1423-1433PubMed
22.
Anderson CJ. The psychology of doing nothing: forms of decision avoidance result from reason and emotion.  Psychol Bull. 2003;129(1):139-167PubMedArticle
23.
Redelmeier DA, Shafir E. Medical decision making in situations that offer multiple alternatives.  JAMA. 1995;273(4):302-305PubMedArticle
24.
Jones RM, Vernon SW, Woolf SH. Is discussion of colorectal cancer screening options associated with heightened patient confusion?  Cancer Epidemiol Biomarkers Prev. 2010;19(11):2821-2825PubMedArticle
25.
Inadomi JM, Kuhn L, Vijan S, Fendrick AM, McMahon LF, Hayward RA. Adherence to competing colorectal cancer screening strategies.  Am J Gastroenterol. 2005;100:S387-S388
26.
Segnan N, Senore C, Andreoni B,  et al; SCORE2 Working Group-Italy.  Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.  J Natl Cancer Inst. 2005;97(5):347-357PubMedArticle
27.
Segnan N, Senore C, Andreoni B,  et al; SCORE3 Working Group-Italy.  Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening.  Gastroenterology. 2007;132(7):2304-2312PubMedArticle
28.
Ioannou GN, Chapko MK, Dominitz JA. Predictors of colorectal cancer screening participation in the United States.  Am J Gastroenterol. 2003;98(9):2082-2091PubMedArticle
29.
Seeff LC, Nadel MR, Klabunde CN,  et al.  Patterns and predictors of colorectal cancer test use in the adult US population.  Cancer. 2004;100(10):2093-2103PubMedArticle
30.
O’Malley AS, Forrest CB, Feng S, Mandelblatt J. Disparities despite coverage: gaps in colorectal cancer screening among Medicare beneficiaries.  Arch Intern Med. 2005;165(18):2129-2135PubMedArticle
31.
Franzini L, Ribble JC, Keddie AM. Understanding the Hispanic paradox.  Ethn Dis. 2001;11(3):496-518PubMed
32.
Schwartz B. The Paradox of Choice: Why More Is Less. New York, NY: Ecco; 2004
33.
Iyengar S. The Art of Choosing. New York, NY: Twelve; 2010
Original Investigation
Apr 9, 2012

Adherence to Colorectal Cancer ScreeningA Randomized Clinical Trial of Competing Strategies

Author Affiliations

Author Affiliations: Division of Gastroenterology, Department of Medicine, University of Washington, Seattle (Dr Inadomi); GI Health Outcomes, Policy and Economics (HOPE) Research Program, Department of Medicine, University of California, San Francisco (Drs Inadomi, Somsouk, and El-Nachef and Mss Thomas, Lin, Muñoz, and Lau); Division of Gastroenterology, San Francisco General Hospital, San Francisco (Drs Inadomi, Somsouk, and El-Nachef and Mss Thomas, Lin, Muñoz, and Lau); Department of Veteran Affairs Ann Arbor Health Services Research and Development Center of Excellence, Ann Arbor, Michigan (Drs Vijan, Fagerlin, and Hayward); and Department of Medicine (Drs Vijan, Fagerlin, and Hayward) and School of Public Health (Dr Janz), University of Michigan, Ann Arbor.

Arch Intern Med. 2012;172(7):575-582. doi:10.1001/archinternmed.2012.332
×